Additionally, since only RA twins but not healthy co-twins had been treated, the difference in IgA-EBNA1 antibody level between healthy, but RA-predisposed co-twins, and the population of healthy twins cannot be ascribed to an effect of treatment. This evidence concerns the gene CD79A and rheumatoid arthritis.